JP2019516966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516966A5 JP2019516966A5 JP2018554391A JP2018554391A JP2019516966A5 JP 2019516966 A5 JP2019516966 A5 JP 2019516966A5 JP 2018554391 A JP2018554391 A JP 2018554391A JP 2018554391 A JP2018554391 A JP 2018554391A JP 2019516966 A5 JP2019516966 A5 JP 2019516966A5
- Authority
- JP
- Japan
- Prior art keywords
- acetylglucosamine
- apo
- lectin
- level
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 34
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 21
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 21
- 230000000302 ischemic effect Effects 0.000 claims 20
- 102000004856 Lectins Human genes 0.000 claims 17
- 108090001090 Lectins Proteins 0.000 claims 17
- 239000002523 lectin Substances 0.000 claims 17
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 16
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 15
- 239000003153 chemical reaction reagent Substances 0.000 claims 14
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims 11
- 125000005629 sialic acid group Chemical group 0.000 claims 6
- 101100440173 Mus musculus Clu gene Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000029078 coronary artery disease Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 3
- 150000004676 glycans Chemical group 0.000 claims 3
- 208000031225 myocardial ischemia Diseases 0.000 claims 3
- 238000004393 prognosis Methods 0.000 claims 3
- 230000000306 recurrent effect Effects 0.000 claims 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 3
- 230000000451 tissue damage Effects 0.000 claims 3
- 231100000827 tissue damage Toxicity 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 240000008853 Datura stramonium Species 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 235000021307 Triticum Nutrition 0.000 claims 2
- 241000209140 Triticum Species 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000034994 death Effects 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000004302 Microvascular Angina Diseases 0.000 claims 1
- 208000026018 Microvascular coronary artery disease Diseases 0.000 claims 1
- WSSMMNVKLQZMEF-BEKOLJTOSA-N N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O WSSMMNVKLQZMEF-BEKOLJTOSA-N 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382167.1 | 2016-04-12 | ||
| EP16382167.1A EP3232200A1 (en) | 2016-04-12 | 2016-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
| PCT/EP2017/058768 WO2017178521A1 (en) | 2016-04-12 | 2017-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516966A JP2019516966A (ja) | 2019-06-20 |
| JP2019516966A5 true JP2019516966A5 (enExample) | 2021-04-08 |
| JP7075894B2 JP7075894B2 (ja) | 2022-05-26 |
Family
ID=56008566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554391A Active JP7075894B2 (ja) | 2016-04-12 | 2017-04-12 | 虚血を有する患者の診断およびリスク層別化のための方法およびキット |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11486884B2 (enExample) |
| EP (2) | EP3232200A1 (enExample) |
| JP (1) | JP7075894B2 (enExample) |
| KR (1) | KR102344344B1 (enExample) |
| CN (1) | CN109154620B (enExample) |
| AU (1) | AU2017251355A1 (enExample) |
| BR (1) | BR112018070971A2 (enExample) |
| CA (1) | CA3020666A1 (enExample) |
| ES (1) | ES2979390T3 (enExample) |
| IL (1) | IL262245B (enExample) |
| MA (1) | MA44658A (enExample) |
| MX (1) | MX2018012580A (enExample) |
| RU (1) | RU2750035C2 (enExample) |
| SG (1) | SG11201808820QA (enExample) |
| WO (1) | WO2017178521A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022506108A (ja) * | 2018-10-23 | 2022-01-17 | グリカルディアル ダイアグノスティクス エセ． エレ． | グリコシル化ＡｐｏＪに特異的な抗体およびその使用 |
| WO2020115095A2 (en) * | 2018-12-05 | 2020-06-11 | Glycardial Diagnostics, S.L. | Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury |
| KR102158726B1 (ko) | 2019-04-17 | 2020-09-22 | 한림대학교 산학협력단 | Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물 |
| KR102281657B1 (ko) | 2019-12-23 | 2021-07-26 | 한림대학교 산학협력단 | 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커 |
| KR102281644B1 (ko) | 2019-12-23 | 2021-07-23 | 한림대학교 산학협력단 | 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커 |
| KR102312534B1 (ko) | 2019-12-31 | 2021-10-13 | 한림대학교 산학협력단 | 뇌척수액 유래 미토콘드리아 마커를 이용한 지연성 허혈 진단 방법 |
| KR102318236B1 (ko) | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법 |
| KR102336507B1 (ko) | 2020-02-21 | 2021-12-06 | 한림대학교 산학협력단 | 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법 |
| KR102369155B1 (ko) | 2020-07-07 | 2022-02-28 | 한림대학교 산학협력단 | 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법 |
| KR102473349B1 (ko) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 kifap3 유전자 과메틸화 마커 |
| KR102473350B1 (ko) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커 |
| KR102496589B1 (ko) | 2020-09-11 | 2023-02-03 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 vhl 유전자 과메틸화 마커 |
| KR102473348B1 (ko) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커 |
| KR102477500B1 (ko) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 oprm1 유전자 과메틸화 마커 |
| KR102477501B1 (ko) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 alb 유전자 저메틸화 마커 |
| KR102477502B1 (ko) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커 |
| KR102466956B1 (ko) | 2020-11-05 | 2022-11-11 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 dapk1 바이오마커 |
| KR102470789B1 (ko) | 2020-11-05 | 2022-11-25 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 pink1 바이오마커 |
| KR102398533B1 (ko) | 2020-11-05 | 2022-05-13 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 뇌척수액 마이토파지 마커 |
| KR102398534B1 (ko) | 2020-11-05 | 2022-05-13 | 한림대학교 산학협력단 | 지연성 뇌허혈 진단을 위한 bnip3l 바이오마커 |
| CN113462744B (zh) * | 2021-05-24 | 2023-06-23 | 中国药科大学 | N-乙酰葡萄糖胺作为标志物在制备诊断缺血性脑中风试剂中的应用 |
| KR102865129B1 (ko) | 2021-08-06 | 2025-09-26 | 에이치앤비지노믹스 주식회사 | 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140045A (en) | 1995-03-10 | 2000-10-31 | Meso Scale Technologies | Multi-array, multi-specific electrochemiluminescence testing |
| CA2301634A1 (en) * | 1997-07-15 | 1999-01-28 | Pradeep Ghosh | Determining alcohol intake using sialic acid/apo j |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| EP1746902A4 (en) * | 2004-05-05 | 2007-06-13 | Univ Northeastern | MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF |
| JP6028960B2 (ja) * | 2009-07-14 | 2016-11-24 | 国立研究開発法人産業技術総合研究所 | 肝疾患病態指標糖鎖マーカー |
| ES2364169B1 (es) | 2010-02-09 | 2012-07-10 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) | Uso de las isoformas de apo j como biomarcadores de lesión tisular. |
| EP2400304A1 (en) * | 2010-06-22 | 2011-12-28 | Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) | Method for the characterization of intermolecular interactions |
| JP2012107932A (ja) | 2010-11-16 | 2012-06-07 | Mitsubishi Chemicals Corp | Ｃｌｕｓｔｅｒｉｎ蛋白質による脳梗塞の検査方法 |
| DK3289363T3 (da) | 2015-04-30 | 2022-02-28 | Idexx Lab Inc | Specifik påvisning af clusterin isoformer |
| CN107957498A (zh) * | 2016-10-18 | 2018-04-24 | 厦门德馨尚品医疗科技有限公司 | 一种含有载脂蛋白j的试剂盒及其在临床诊断中的应用 |
-
2016
- 2016-04-12 EP EP16382167.1A patent/EP3232200A1/en not_active Withdrawn
-
2017
- 2017-04-12 MX MX2018012580A patent/MX2018012580A/es unknown
- 2017-04-12 US US16/092,703 patent/US11486884B2/en active Active
- 2017-04-12 JP JP2018554391A patent/JP7075894B2/ja active Active
- 2017-04-12 AU AU2017251355A patent/AU2017251355A1/en not_active Abandoned
- 2017-04-12 CA CA3020666A patent/CA3020666A1/en active Pending
- 2017-04-12 SG SG11201808820QA patent/SG11201808820QA/en unknown
- 2017-04-12 BR BR112018070971A patent/BR112018070971A2/pt not_active Application Discontinuation
- 2017-04-12 ES ES17717159T patent/ES2979390T3/es active Active
- 2017-04-12 EP EP17717159.2A patent/EP3443353B1/en active Active
- 2017-04-12 KR KR1020187032609A patent/KR102344344B1/ko not_active Expired - Fee Related
- 2017-04-12 WO PCT/EP2017/058768 patent/WO2017178521A1/en not_active Ceased
- 2017-04-12 MA MA044658A patent/MA44658A/fr unknown
- 2017-04-12 CN CN201780029342.8A patent/CN109154620B/zh not_active Expired - Fee Related
- 2017-04-12 RU RU2018139780A patent/RU2750035C2/ru active
-
2018
- 2018-10-09 IL IL262245A patent/IL262245B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516966A5 (enExample) | ||
| Bivona et al. | Biomarkers for prognosis and treatment response in COVID-19 patients | |
| Qu et al. | Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer’s disease: A systematic review and meta-analysis | |
| Dähnrich et al. | Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy | |
| Nickel et al. | The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department | |
| Thygesen et al. | Recommendations for the use of cardiac troponin measurement in acute cardiac care | |
| Yang et al. | Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction | |
| JP2019535015A5 (enExample) | ||
| Oran et al. | Ischemia‐Modified Albumin as a Marker of Acute Coronary Syndrome: The Case for Revising the Concept of “N‐Terminal Modification” to “Fatty Acid Occupation” of Albumin | |
| Lim et al. | An electrochemical biosensor for detection of the sepsis-related biomarker procalcitonin | |
| RU2018139780A (ru) | Способы и наборы диагностики и стратификации риска пациентов с ишемией | |
| CN103946709B (zh) | 基于l-fabp诊断急性事件后或外科手术后的肾损伤 | |
| JP2009501333A5 (enExample) | ||
| EP2836841A1 (en) | Prognosis of adverse events in patients with suspected chronic heart failure | |
| Lau et al. | Qualification and application of an ELISA for the determination of Tamm Horsfall protein (THP) in human urine and its use for screening of kidney stone disease | |
| Omland | New features of troponin testing in different clinical settings | |
| Furuya et al. | Analytical validation of ONCURIA™ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection | |
| Vashist | Graphene-based immunoassay for human lipocalin-2 | |
| Prashanth et al. | Clinical significance of ischemia modified albumin in critically ill patients with sepsis | |
| CN104272112B (zh) | 用于帮助诊断中风的基于生物标记的方法和生物芯片 | |
| WO2003081236B1 (en) | Method and device for predicting cardiovascular events | |
| WO2013023233A1 (en) | Method for diagnosis, prognosis or treatment of acute coronary syndrome (acs) comprising measurement of plasma concentration of macrophage migration inhibitory factor (mif) | |
| JP5686431B2 (ja) | 卵巣癌の検出方法、並びに、キット | |
| Lippi et al. | Diagnostic value of D-dimer measurement in patients referred to the emergency department with suspected myocardial ischemia | |
| Wu et al. | Development of an alpha-fetoprotein and Golgi protein 73 multiplex detection assay using xMAP technology |